Bayer receives positive opinion from European Medicines Agency for Baycox Iron injection for piglets

The Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has, by consensus, adopted a positive opinion recommending marketing authorisation for the veterinary medicinal product Baycox Iron (36 mg/ml toltrazuril plus 182 mg/ml gleptoferron) suspension for injection for piglets.

If granted marketing approval by the European Commission, Baycox Iron suspension for injection will be an innovative combination for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and prevention of iron deficiency anaemia. Detailed conditions of the product will be described in the summary of product characteristics (SPC), which will be published together with the European public assessment report (EPAR) after approval.